一项关于静脉注射6-硫鸟嘌呤（NSC-752）治疗多发性骨髓瘤的II期研究。西南肿瘤协作组的一项研究。
A-phase II study of intravenous 6-thioguanine (NSC-752) in multiple myeloma. A Southwest Oncology Group study.
作者信息
Edelstein M B, Crowley J J, Valeriote F A, Bonnet J D, Carden J O, Khanna R C, Salmon S E, Ungerleider J S
机构信息
Wayne State University Medical Center, Seattle.
出版信息
Invest New Drugs. 1990;8 Suppl 1:S83-6. doi: 10.1007/BF00171990.
Thirty-three patients with relapsing or refractory multiple myeloma were treated with 6-Thioguanine (6TG) at a dose of 1 g/M2, with therapy given over four hours every three weeks. The major toxicity seen was myelotoxicity; thrombocytopenia was more commonly noted than neutropenia. One patient achieved a PR, two were clinically improved. 6TG in this short infusion schedule proved to be myelotoxic, but demonstrated little activity in previously treated myeloma patients.
33例复发或难治性多发性骨髓瘤患者接受了6-硫鸟嘌呤（6TG）治疗，剂量为1 g/M2，每三周进行一次为期四小时的治疗。观察到的主要毒性是骨髓毒性；血小板减少比中性粒细胞减少更常见。1例患者达到部分缓解（PR），2例患者临床症状改善。这种短程输注方案的6TG被证明具有骨髓毒性，但在先前治疗过的骨髓瘤患者中几乎没有活性。
Zotero 插件